SINGLE-CENTER EXPERIENCE: Use of Recombinant Factor VIIa for Acute Life-Threatening Bleeding in Children without Congenital Hemorrhagic Disorder

REFERENCES

• Aird W C. Coagulopathy. Textbook of Critical Care ed. 5, M P Fink, E Abraham, J L Vincent, P M Kochanek. Elsevier & Saunders, Philadelphia 2005; 97–99
   Google Scholar
• Kenet G, Walden R, Eldad A, Martinowitz U. Treatment of traumatic bleeding with recombinant factor VIIa. Lancet 1999; 354: 1879
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Kenet G, Segal E, et al. Recombinant activated factor VII for adjunctive hemorrhage control in trauma. J Trauma. 2001; 51: 431–439
   PubMed Web of Science ®Google Scholar
• Romero-Castro R, Jimenez-Saenz M, Pellicer-Bautista F, et al. Recombinant-activated factor VII as hemostatic therapy in eight cases of severe hemorrhage from eosephegeal varices. Clin Gastroenterol Hepatol. 2004; 2: 78–84
   PubMed Web of Science ®Google Scholar
• Bosch J, Thabut D, Bendsen F, and et alx˙ the European Study Group on rFVIIa in UGI Haemorrhage. Recombinant factor VIIa for upper gastrointestinal bleeding in patients with cirrhosis: a randomized, double blind trial. Gastroenterology 2004; 127: 1123–1130
   PubMed Web of Science ®Google Scholar
• Ejlersen E, Melsen T, Ingerslev J, Andreasen R B, Vilstrup H. Recombinant activated factor VII (rFVIIa) acutely normalizes prothrombin time in patients with cirrhosis during bleeding from oesophageal varices. Scand J Gastroenterol. 2001; 10: 1081–1085
   Google Scholar
• Jeffers L, Chalasani N, Balart L, Pyrsopoulos N, Erhardtsen E. Safety and efficacy of recombinant factor VIIa in patients undergoing laparoscopic liver biopsy. Gastroenterology 2002; 123: 118–126
   PubMed Web of Science ®Google Scholar
• White B, McHale J, Ravi N, Reynolds J, Stephens R, Moriarty J, Smith O P. Successful use of recombinant factor VIIa (Novoseven) in the management of intractable post-surgical intra-abdominal hemorrhage. Br J Haematol. 1999; 107: 677–678
   PubMed Web of Science ®Google Scholar
• Friederich P W, Henry C P, Messelink E J, et al. Effect of recombinant activated factor VII on perioperative blood loss in patients undergoing retropubic prostatectomy: a double blind placebo-controlled randomized trial. Lancet 2003; 361: 201–205
   PubMed Web of Science ®Google Scholar
• Hunseler C, Kribs A, Eifinger F, Roth B. Recombinant activated factor seven in acute life-threatening bleeding in neonates: report on three cases and review of literature. J Perinatol. 2006; 26: 706–713
   PubMedGoogle Scholar
• Voldman A, Fischer D, Voigt B, et al. Life threatening hemorrhage in neonates: management with recombinant activated factor VII. Intensive Care Med. 2002; 28: 635–637
   Google Scholar
• Brody K M, Easley R B, Tobias J D. Recombinant activated factor VII (rFVIIa) treatment in infants with hemorrhage. Paediatr Anaesth 2006; 16: 1042–1046
   PubMedGoogle Scholar
• Pettersson M, Fischler B, Petrini P, Schulman S, Nemeth A. Recombinant FVIIa in children with liver disease. Thromb Res 2005; 116: 185–197
   PubMedGoogle Scholar
• Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score, prospective, observational, multicenter study. Lancet 2003; 362: 192–197
   PubMed Web of Science ®Google Scholar
• Uhlmann E J, Eby C S. Recombinant activated factor VII for non-hemophiliac bleeding patients. Curr Opin Hematol 2004; 11: 198–204
   PubMed Web of Science ®Google Scholar
• Mittal S, Watson H G. A critical appraisal of the use of recombinant factor VIIa in acquired bleeding conditions. Br J Haematol. 2006; 133: 355–363
   PubMed Web of Science ®Google Scholar
• Hicks K, Peng D, Gajewski J L. Treatment of diffuse alveolar hemorrhage after allogeneic bone marrow transplant with recombinant factor VIIa. Bone Marrow Transplant 2002; 30: 975–978
   PubMed Web of Science ®Google Scholar
• Martinowitz U, Michaelson M. Guidelines for the use of recombinant activated factor VII (rFVIIa) in uncontrolled bleeding: a report by the Israeli Multidisciplinary rFVIIa Task Force. J Thromb Haemost. 2005; 3: 640–648
   PubMed Web of Science ®Google Scholar
• Enomoto T M, Thorborg P. Emerging off-label uses for recombinant activated factor VII: grading the evidence. Crit Care Clin. 2005; 21: 611–632
   PubMedGoogle Scholar
• Dutton R P, Stein D. The use of factor VIIa in haemorrhagic shock and intracerebral bleeding. Injury 2006; 37: 1172–1177
   PubMedGoogle Scholar
• Mayo A, Misgav M, Kluger Y, Geenberg R, Pauzner D, Klausner J, Ben-Tal O. Recombinant activated factor VII (NovoSevenTM): addition to replacement therapy in acute, uncontrolled and life-threateninmg bleeding. Vox Sang 2004; 87: 34–40
   PubMed Web of Science ®Google Scholar
• Chiara O, Cimbanassi S, Brioschi P R, Bucci L, Terzi V, Vesconi S. Treatment of critical bleeding in trauma patients. Minerva Anestesiol. 2006; 72: 383–387
   PubMedGoogle Scholar
• Vlot A J, Ton E, Mackaay A J, Kramer M H, Gaillard C A. Treatment of a severely bleeding patient without preexisting coagulopathy with activated recombinant factor VII. Am J Med. 2000; 108: 421–423
   PubMed Web of Science ®Google Scholar
• Pepe Judith. Central venous catheterization. Textbook of Critical Care ed. 5, M P Fink, E Abraham, J L Vincent, P M Kochanek. Elsevier & Saunders, Philadelphia 2005; 1785–1790
   Google Scholar
• Clark A D, Gordon W C, Walker I D, Tait R C. “Last-ditch” use of recombinant factor VIIa in patients with massive hemorrhage is ineffective. Vox Sang 2004; 86: 120–124
   PubMed Web of Science ®Google Scholar
• Cengiz P, Zimmerman J J. Pediatric multiple organ dysfunction syndrome. Pediatric Critical Care ed. 3, B P Fuhrman, J Zimmerman. Mosby & Elsevier, Philadelphia 2006; 1494–1507
   Google Scholar
• Barnes C, Blanchette V, Canning P, Carcao M. Recombinant FVIIa in the management of intra-cerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med. 2005; 15: 145–150
   PubMedGoogle Scholar
• Aledort L. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost. 2004; 2: 1700–1708
   PubMed Web of Science ®Google Scholar
• Ganguly S, Spengel K, Tilzer L L, O’ Neal B, Simpson S Q. Recombinant factor VIIa: unregulated continuous use in patients with bleeding and coagulopathy does not alter mortality and outcome. Clin Lab Haematol. 2006; 28: 309–312
   PubMedGoogle Scholar
• Meng Z H, Wolberg A S III, Monroe D M, Hoffman M. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypotermic and acidotic patients. J Trauma 2003; 55: 886–891
   PubMedGoogle Scholar